Vaxcyte, Inc. (NASDAQ:PCVX) Receives $86.00 Average Price Target from Brokerages

Shares of Vaxcyte, Inc. (NASDAQ:PCVX) have received a consensus rating of “Hold” from the nine research firms that are covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $86.00.

PCVX has been the topic of a number of analyst reports. Zacks Research downgraded shares of Vaxcyte from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. Wall Street Zen downgraded shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a report on Tuesday, April 28th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a research report on Monday, July 6th.

Vaxcyte News Summary

Here are the key news stories impacting Vaxcyte this week:

• Positive Sentiment: Quarterly loss beat expectations: Vaxcyte reported second-quarter 2026 EPS of negative $1.97, better than analysts’ consensus estimate of negative $2.06. However, the loss was wider than the negative $1.22 reported in the year-earlier quarter. Vaxcyte quarterly earnings release
• Positive Sentiment: Multiple clinical catalysts are ahead: Topline safety, tolerability and immunogenicity data from the VAX-31 adult Phase 3 OPUS-1 trial are expected in the fourth quarter of 2026. Results from OPUS-2 and OPUS-3 are expected in the first half of 2027, while infant VAX-31 data are expected by the end of the first half of 2027. Vaxcyte second-quarter business update
• Positive Sentiment: Strong liquidity supports development: Vaxcyte held approximately $2.5 billion in cash, cash equivalents and investments at June 30, 2026. The balance sheet reduces near-term financing concerns as the company advances its late-stage vaccine programs and VAX-A1.
• Neutral Sentiment: Institutional ownership remains high: Several funds, including Royal Bank of Canada, UBS Asset Management and Cetera Investment Advisers, increased their positions recently. Institutional investors and hedge funds collectively own approximately 96.8% of outstanding shares.
• Negative Sentiment: Executives reported stock sales: The CFO, COO and another insider sold a combined 29,250 shares worth roughly $1.6 million. The transactions were made under pre-arranged Rule 10b5-1 plans, limiting their significance, but the sales may still weigh modestly on sentiment. Vaxcyte insider selling report
• Negative Sentiment: Losses are expected to continue: Analysts forecast a full-year 2026 loss of approximately $7.91 per share, underscoring Vaxcyte’s dependence on successful clinical execution and future commercialization.

Vaxcyte Stock Up 5.3%

PCVX stock opened at $58.89 on Tuesday. The firm has a market capitalization of $8.50 billion, a PE ratio of -7.72 and a beta of 1.23. Vaxcyte has a twelve month low of $29.08 and a twelve month high of $65.00. The stock’s 50 day moving average is $53.72 and its 200-day moving average is $55.19.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.06) by $0.09. During the same period in the prior year, the company posted ($1.22) EPS. On average, equities research analysts anticipate that Vaxcyte will post -7.91 earnings per share for the current fiscal year.

Insider Activity

In other Vaxcyte news, insider Harpreet S. Dhaliwal sold 17,000 shares of Vaxcyte stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $55.00, for a total transaction of $935,000.00. Following the transaction, the insider owned 76,756 shares of the company’s stock, valued at $4,221,580. This trade represents a 18.13% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Grant Pickering sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $55.65, for a total value of $111,300.00. Following the completion of the transaction, the chief executive officer owned 133,215 shares in the company, valued at $7,413,414.75. The trade was a 1.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 120,646 shares of company stock valued at $6,570,810. 3.30% of the stock is currently owned by company insiders.

Institutional Trading of Vaxcyte

A number of institutional investors and hedge funds have recently modified their holdings of the business. Smartleaf Asset Management LLC boosted its position in Vaxcyte by 156.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock worth $27,000 after purchasing an additional 364 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its position in shares of Vaxcyte by 1,463.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock valued at $30,000 after purchasing an additional 600 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Vaxcyte by 33.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock valued at $34,000 after purchasing an additional 184 shares during the last quarter. Capital Advisors Ltd. LLC purchased a new stake in shares of Vaxcyte during the 1st quarter valued at $58,000. Finally, CIBC Private Wealth Group LLC raised its stake in shares of Vaxcyte by 22,500.0% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,356 shares of the company’s stock worth $49,000 after purchasing an additional 1,350 shares during the period. 96.78% of the stock is owned by hedge funds and other institutional investors.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.